Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × Bortezomib × 90 days × Clear all

NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase 2 Completed

Lymphoma, B-Cell, Marginal Zone